Early prostate cancer: Prevention, treatment modalities, and quality of life issues

J. W. Moul, J. Anderson, D. F. Penson, L. H. Klotz, M. S. Soloway, C. C. Schulmanf

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Our understanding of the screening, prevention and treatment of early prostate cancer is improving. This is a result of new data from clinical trials and the incorporation of efficacy measures based on risk assessment and quality of life (QoL). This review aims to examine completed and ongoing clinical trials that address issues in early prostate cancer, including screening, prevention, treatment, and QoL. Prostate-specific antigen (PSA) testing has a crucial and evolving role in detecting primary prostate cancer, evaluating prevention interventions and assessing the effectiveness of treatment. Questions remain about the optimal PSA parameters appropriate for primary screening and for diagnosing relapse. Emerging and established data provide evidence that early intervention with hormone therapy, either as immediate or adjuvant therapy, delays progression in prostate cancer patients with intermediate or poor prognosis. The impact of therapeutic modality on QoL has become better characterized, as QoL instruments have been developed, validated and applied.

Original languageEnglish
Pages (from-to)283-293
Number of pages11
JournalEuropean Urology
Volume44
Issue number3
DOIs
StatePublished - Sep 1 2003
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Quality of Life
Prostate-Specific Antigen
Clinical Trials
Therapeutics
Early Detection of Cancer
Hormones
Recurrence

Keywords

  • Antiandrogen therapy
  • Biochemical relapse
  • Early prostate cancer
  • Prevention
  • Prostate-specific antigen
  • Quality of life
  • Screening
  • Treatment

ASJC Scopus subject areas

  • Urology

Cite this

Moul, J. W., Anderson, J., Penson, D. F., Klotz, L. H., Soloway, M. S., & Schulmanf, C. C. (2003). Early prostate cancer: Prevention, treatment modalities, and quality of life issues. European Urology, 44(3), 283-293. https://doi.org/10.1016/S0302-2838(03)00296-3

Early prostate cancer : Prevention, treatment modalities, and quality of life issues. / Moul, J. W.; Anderson, J.; Penson, D. F.; Klotz, L. H.; Soloway, M. S.; Schulmanf, C. C.

In: European Urology, Vol. 44, No. 3, 01.09.2003, p. 283-293.

Research output: Contribution to journalArticle

Moul, JW, Anderson, J, Penson, DF, Klotz, LH, Soloway, MS & Schulmanf, CC 2003, 'Early prostate cancer: Prevention, treatment modalities, and quality of life issues', European Urology, vol. 44, no. 3, pp. 283-293. https://doi.org/10.1016/S0302-2838(03)00296-3
Moul JW, Anderson J, Penson DF, Klotz LH, Soloway MS, Schulmanf CC. Early prostate cancer: Prevention, treatment modalities, and quality of life issues. European Urology. 2003 Sep 1;44(3):283-293. https://doi.org/10.1016/S0302-2838(03)00296-3
Moul, J. W. ; Anderson, J. ; Penson, D. F. ; Klotz, L. H. ; Soloway, M. S. ; Schulmanf, C. C. / Early prostate cancer : Prevention, treatment modalities, and quality of life issues. In: European Urology. 2003 ; Vol. 44, No. 3. pp. 283-293.
@article{221ec7bd82a54ce4864ea48bb96be940,
title = "Early prostate cancer: Prevention, treatment modalities, and quality of life issues",
abstract = "Our understanding of the screening, prevention and treatment of early prostate cancer is improving. This is a result of new data from clinical trials and the incorporation of efficacy measures based on risk assessment and quality of life (QoL). This review aims to examine completed and ongoing clinical trials that address issues in early prostate cancer, including screening, prevention, treatment, and QoL. Prostate-specific antigen (PSA) testing has a crucial and evolving role in detecting primary prostate cancer, evaluating prevention interventions and assessing the effectiveness of treatment. Questions remain about the optimal PSA parameters appropriate for primary screening and for diagnosing relapse. Emerging and established data provide evidence that early intervention with hormone therapy, either as immediate or adjuvant therapy, delays progression in prostate cancer patients with intermediate or poor prognosis. The impact of therapeutic modality on QoL has become better characterized, as QoL instruments have been developed, validated and applied.",
keywords = "Antiandrogen therapy, Biochemical relapse, Early prostate cancer, Prevention, Prostate-specific antigen, Quality of life, Screening, Treatment",
author = "Moul, {J. W.} and J. Anderson and Penson, {D. F.} and Klotz, {L. H.} and Soloway, {M. S.} and Schulmanf, {C. C.}",
year = "2003",
month = "9",
day = "1",
doi = "10.1016/S0302-2838(03)00296-3",
language = "English",
volume = "44",
pages = "283--293",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Early prostate cancer

T2 - Prevention, treatment modalities, and quality of life issues

AU - Moul, J. W.

AU - Anderson, J.

AU - Penson, D. F.

AU - Klotz, L. H.

AU - Soloway, M. S.

AU - Schulmanf, C. C.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Our understanding of the screening, prevention and treatment of early prostate cancer is improving. This is a result of new data from clinical trials and the incorporation of efficacy measures based on risk assessment and quality of life (QoL). This review aims to examine completed and ongoing clinical trials that address issues in early prostate cancer, including screening, prevention, treatment, and QoL. Prostate-specific antigen (PSA) testing has a crucial and evolving role in detecting primary prostate cancer, evaluating prevention interventions and assessing the effectiveness of treatment. Questions remain about the optimal PSA parameters appropriate for primary screening and for diagnosing relapse. Emerging and established data provide evidence that early intervention with hormone therapy, either as immediate or adjuvant therapy, delays progression in prostate cancer patients with intermediate or poor prognosis. The impact of therapeutic modality on QoL has become better characterized, as QoL instruments have been developed, validated and applied.

AB - Our understanding of the screening, prevention and treatment of early prostate cancer is improving. This is a result of new data from clinical trials and the incorporation of efficacy measures based on risk assessment and quality of life (QoL). This review aims to examine completed and ongoing clinical trials that address issues in early prostate cancer, including screening, prevention, treatment, and QoL. Prostate-specific antigen (PSA) testing has a crucial and evolving role in detecting primary prostate cancer, evaluating prevention interventions and assessing the effectiveness of treatment. Questions remain about the optimal PSA parameters appropriate for primary screening and for diagnosing relapse. Emerging and established data provide evidence that early intervention with hormone therapy, either as immediate or adjuvant therapy, delays progression in prostate cancer patients with intermediate or poor prognosis. The impact of therapeutic modality on QoL has become better characterized, as QoL instruments have been developed, validated and applied.

KW - Antiandrogen therapy

KW - Biochemical relapse

KW - Early prostate cancer

KW - Prevention

KW - Prostate-specific antigen

KW - Quality of life

KW - Screening

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0041857999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041857999&partnerID=8YFLogxK

U2 - 10.1016/S0302-2838(03)00296-3

DO - 10.1016/S0302-2838(03)00296-3

M3 - Article

C2 - 12932925

AN - SCOPUS:0041857999

VL - 44

SP - 283

EP - 293

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 3

ER -